Novo Nordisk is a global pharmaceutical company with a 95-year history of diabetes innovation and leadership. More than 29.2 million patients in 170 countries use Novo Nordisk’s diabetes products daily, one in every two patients in the world. The company also holds leading positions in the areas of hemostasis management, growth hormone therapy, hormone replacement therapy for women, and obesity.
The headquarters of Novo Nordisk is located in Denmark. 43,200 employees work in 80 branches of the company worldwide, and its products are delivered to 170 countries.
Novo Nordisk Type B shares are listed on the NASDAQ OMX Copenhagen (Novo-B) Stock Exchange. American Depositary Receipts (ADRs) are traded on the New York Stock Exchange (NVO).